Boehringer Ingelheim plans to expand R&D and pharmaceutical manufacturing, ensuring the majority of its medicines for U.S. patients will be produced in the U.S.
RIDGEFIELD, Conn., Dec. 19, 2025 — Boehringer Ingelheim, a 140-year-old family-owned biopharmaceutical firm dedicated to enhancing human and animal health and driving innovation, today disclosed a comprehensive agreement with the Trump Administration to reduce medication costs for American patients, aligning with the terms outlined by the U.S. President in his July 31, 2025, letter to the pharmaceutical industry. This includes involvement in a direct purchasing platform, TrumpRx.gov, which will enable American patients to buy Boehringer medicines at a substantial discount.
Boehringer will allocate $10 billion by 2028 to expand its pharmaceutical R&D and manufacturing operations in the U.S., with $1 billion earmarked specifically for capital expenditures. This investment is part of Boehringer’s larger six-year strategy to invest $20 billion across both its human pharmaceuticals and animal health businesses in the U.S. The agreement with the U.S. administration exempts Boehringer Ingelheim from potential Section 232 tariffs.
“Boehringer Ingelheim has a longstanding history of addressing chronic illnesses and supporting patients throughout their care journey. Approximately 70 million Americans are affected by cardiovascular, renal, and metabolic diseases, with 35 million of these individuals living with chronic kidney disease (CKD). Most are unaware of their CKD until damage has occurred, resulting in poor health outcomes,” said Jean-Michel Boers, President and CEO, Boehringer Ingelheim, USA Corporation. “We wish to express our gratitude to the President and his administration for their constructive engagement in achieving lower medication costs, as well as increased investment in the U.S. pharmaceutical sector, which will create more American jobs. And most crucially: This agreement helps ensure that patients receive the medicines they need, when they need them.”
“Health is among the most impactful investments any society can make. Annually, we reach millions of individuals living with chronic, interconnected conditions that demand integrated care. Today’s voluntary agreement strengthens the supply chain for life-altering medicines while bolstering the foundations for medical innovation in the U.S.,” said Shashank Deshpande, Chairman of the Boehringer Ingelheim Board of Managing Directors. “We must now enhance the resilience and sustainability of global health systems to ensure that pharmaceutical innovation can continue to flourish.”
Boehringer is a leader in the industry’s research and development efforts, focusing not only on innovative therapies for chronic diseases but also on rare diseases with limited treatment options. In the U.S., the company’s presence spans over 20 sites nationwide, including manufacturing facilities, R&D centers, partner locations, and its U.S. headquarters—situated in Connecticut for Human Pharma and Georgia for Animal Health. Approximately 8,000 employees work for Boehringer across the country.
About Boehringer Ingelheim
Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s leading investors in research and development, the company focuses on developing innovative therapies that can enhance and prolong lives in areas of significant unmet medical need. Independent since its 1885 founding, Boehringer adopts a long-term outlook, integrating sustainability across its entire value chain. Our roughly 54,500 employees serve more than 130 markets to build a healthier and more sustainable future. Learn more at .
Media Contact:
Jennifer Forsyth
Director, Corporate Affairs
E-Mail:
Phone Number: +1 (203) 791-5889
SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.